The first generation of lipid-nanoparticle patents solved getting RNA into cells - mostly the liver, where LNPs naturally accumulate. The 2023 record shows the frontier moving to a harder problem: steering the particle to a chosen organ. That problem opened a new patent neighborhood.
A clear marker is the University of Texas System family: US11590085B2, US11648209B2, and US11648210B2, all titled "Compositions and methods for organ specific delivery of nucleic acids" and issued in 2023. These claim selective organ-targeting lipid nanoparticles - the Siegwart lab's SORT (Selective ORgan Targeting) approach - that redirect delivery to lung, spleen, or other tissues beyond the liver default.
The CPC clustering distinguishes this sub-estate from the generic delivery patents. Alongside the familiar A61K 9/5123 (nanoparticle formulation) and A61K 48/0033 (nucleic-acid delivery), the targeting families add C12N 15/11 / 15/111 / 15/113 (the cargo) and tissue-context limitations. The defining claim element is the lipid modification that biases biodistribution toward a chosen organ.
The strategic point is that organ-selective delivery is a fresh layer of IP, not a redundancy of the existing LNP estate. A program that licensed first-generation delivery still faces these targeting claims if it needs extrahepatic delivery. The white space the field chased - delivering to tissues other than liver - is exactly where this new sub-estate filled in.
For a freedom-to-operate map, the lesson is that 'lipid nanoparticle delivery' is no longer one question. There is the foundational get-into-cells layer (Translate Bio, Moderna, Alnylam, Acuitas) and now a tissue-targeting layer (UT System and others). A program needing organ selectivity must clear both, and the 2023 SORT family is the anchor of the second.